Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase 2 Trial of HY209gel in Atopic Dermatitis Patients
Sponsor: Shaperon
Summary
This is a randomized, double-blind, placebo-controlled, multi-center, phase 2 study in patients with mild to moderate Atopic Dermatitis(AD), which consists of 2 parts.
Official title: A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of HY209 Gel in Patients With Mild to Moderate Atopic Dermatitis(AD)
Key Details
Gender
All
Age Range
18 Years - 100 Years
Study Type
INTERVENTIONAL
Enrollment
210
Start Date
2024-03-01
Completion Date
2026-08-31
Last Updated
2026-02-23
Healthy Volunteers
No
Interventions
HY209GEL Active
Selected two among four doses (HY209GEL 0.5% or 1% or 2% or 4%) in PART1
Placebo
Placebo
Locations (12)
Cahaba Dermatology Skin Health Center
Birmingham, Alabama, United States
RAOOF MD Dermatology
Encino, California, United States
L.A. Universal Research Center, Inc.
Los Angeles, California, United States
Zenith Research Inc.
Los Angeles, California, United States
Continental Clinical Solutions, LLC
Towson, Maryland, United States
Revival Research Institute, LLC
Southfield, Michigan, United States
Sadick Dermatology
New York, New York, United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
Gachon University Gil Medical Center
Seoul, South Korea
Seoul National University Bundang Hospital
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Severance Hospital, Yonsei University Health System
Seoul, South Korea